

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: John William Benbow :

APPLICATION NO.: 10/575,395 : Examiner: To be Assigned

FILING DATE: April 7, 2006 : Group Art Unit: To be Assigned

TITLE: Substituted 2H-[1,2,4]Triazolo[4,3-A]Pyrazines :  
as GSK-3 Inhibitors

Hon. Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

A first office action on the merits has not been received: therefore, no fee for this Information Disclosure Statement is required. In the event that an office action has been mailed, please charge the appropriate fee to Deposit Account No. 16-1445.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a).

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: February 28, 2007

/Carl J. Goddard/  
Carl J. Goddard  
Attorney for Applicant(s)  
Reg. No. 39,203

Pfizer Inc.  
Patent Department, MS 8260-1611  
Eastern Point Road  
Groton, Connecticut 06340  
(860) 441-4902

INFORMATION DISCLOSURE STATEMENT, 9/99, (1/1)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.M./

